0001209191-21-046031.txt : 20210708 0001209191-21-046031.hdr.sgml : 20210708 20210708181823 ACCESSION NUMBER: 0001209191-21-046031 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210706 FILED AS OF DATE: 20210708 DATE AS OF CHANGE: 20210708 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Zuga Matt CENTRAL INDEX KEY: 0001790214 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40551 FILM NUMBER: 211081209 MAIL ADDRESS: STREET 1: C/O TELA BIO, INC. STREET 2: 1 GREAT VALLEY PARKWAY, SUITE 24 CITY: MALVERN STATE: PA ZIP: 19355 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001576885 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 364108129 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4435 NORTH FIRST STREET, SUITE 360 CITY: LIVERMORE STATE: CA ZIP: 94551 BUSINESS PHONE: 925-368-8508 MAIL ADDRESS: STREET 1: 4435 NORTH FIRST STREET, SUITE 360 CITY: LIVERMORE STATE: CA ZIP: 94551 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-07-06 0 0001576885 Acumen Pharmaceuticals, Inc. ABOS 0001790214 Zuga Matt C/O ACUMEN PHARMACEUTICALS, INC. 427 PARK STREET CHARLOTTESVILLE VA 22902 0 1 0 0 Chief Financial Officer Common Stock 2021-07-06 4 C 0 26187 A 26187 D Series A-1 Preferred Stock 2021-07-06 4 C 0 15659 D Common Stock 15659 15659 D Series B Preferred Stock 2021-07-06 4 C 0 10528 D Common Stock 10528 10528 D On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. /s/ Katherine Denby, Attorney-in-Fact 2021-07-08